Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImExHS Limited ( (AU:IME) ) has shared an announcement.
ImExHS Limited reported unaudited full-year 2025 results at the top end of its guidance, with revenue rising 10% to $29.0 million and underlying EBITDA more than tripling to $1.6 million, supported by a strong fourth quarter and a 16% increase in annualised recurring revenue to $34.8 million. Recurring revenue reached $28.5 million on a like-for-like basis, software revenue grew 25% in the fourth quarter excluding one-offs, and the company secured new and renewed enterprise contracts, public-sector tenders in Colombia and Mexico, and expanding partner programme contributions, while improving cash and cutting debt; management highlighted that these gains were achieved despite a volatile Colombian healthcare and FX environment, underscoring stronger execution and momentum into FY26.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
ImExHS Limited (ASX: IME) is a provider of cloud-based medical imaging software and radiology services operating across 18 countries. Its solutions, including the Aquila+ platform enhanced with AI agents, target hospitals, public-sector health institutions and partner channel customers, with a growing emphasis on recurring software revenue and enterprise contracts in markets such as Colombia and Mexico.
Average Trading Volume: 35,720
Technical Sentiment Signal: Buy
Current Market Cap: A$21.62M
For detailed information about IME stock, go to TipRanks’ Stock Analysis page.